Aegerion Pharmaceuticals Inc., of Cambridge, Mass., said patient enrollment was initiated in Japan in a phase III trial of lomitapide as an adjunct treatment to reduce low-density lipoprotein cholesterol (LDL-C) in Japanese patients with homozygous familial hypercholesterolemia (HoFH).